Sign in
Taking people in United StatesNo phase

Studies fat tissue in long COVID, obesity and insulin resistance

Studies fat tissue biopsies for virus and inflammation in adults with long COVID.

Key facts

Who runs it
Stanford University
Where
Palo Alto, United StatesSee the 2 sites
Trial code
Registry title
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Status
Recruiting
People taking part
55 people, planned
Started
6 Jun 2023
Planned end
31 Dec 2025
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Adipose Tissue Biopsy
  • Steady State Plasma Glucose (SSPG) Test
Record updated
4 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 80 with a BMI of 25 or higher who are not pregnant. It studies whether fat tissue plays a role in long COVID.

Age
18 to 80 years
Sex
All sexes can join.
Biomarker or test result
BMI of 25 kg/m2 or higher.

Main reasons for not taking part

  • Currently pregnant
  • Prior liposuction (fat tissue biopsy arm)
  • Weight change of more than 2 kg (4 lb) in one month (fat tissue biopsy arm)
  • Bleeding disorders or use of blood thinners (fat tissue biopsy arm)
  • Healthy control arm only: diabetes, major organ disease, bariatric surgery, eating or psychiatric disorders

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Ages 18 to 80
  • BMI ≥ 25 kg/m2
  • not currently pregnant

Who cannot take part

  • prior liposuction
  • bariatric surgery
  • use of weight loss medication or oral steroids
  • bleeding disorders
  • major organ disease
  • diabetes
  • history of liposuction
  • eating disorders
  • psychiatric disorders
  • fasting glucose >= 126 mg/dL
  • Arm 2 (Adipose Tissue Biopsy) exclusions include
  • pregnancy
  • recent change in weight (> 2 kg in one month)
  • anticoagulant use; Arm 3 (healthy controls only) exclusions include patients with
  • pregnancy or lactation
  • recent change in weight (over the past 12 weeks),
  • hematocrit < 33%
  • blood pressure >160/100 mmHg

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • Clinical and Translational Research UnitPalo Alto, United StatesContact: Nicole Turk, BSEnrolling by invitation
  • Stanford HealthPalo Alto, United StatesContact: Nicole Turk, BSTaking people

About the trial

What the trial wants to find out

The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.

The 3 groups in the trial

  • Chart Review (not actively recruiting)No study treatment, for comparison

    Chart review of previously consented participants from the entire NIH RECOVER cohort, comprised of 15,000 infected and 2,600 noninfected patients across the country.

  • COVID infected and healthy controlsTreatment being tested

    Participants will perform a needle fat biopsy for tissue harvesting in the subacute phase (15-30d) of Covid-19 infection or as a healthy control. Our goal is 20 COVID-19 infected participants and 10 healthy controls.

    Treatment: Adipose Tissue Biopsy

  • Healthy Controls OnlyTreatment being tested

    We are looking for 20 healthy controls for 2 in-person visits on separate days. 1. An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if the participant is insulin-sensitive or insulin resistant. 2. A Needle Fat Biopsy: After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Patients will have a local anesthetic prior to the procedure.

    Treatment: Adipose Tissue Biopsy and Steady State Plasma Glucose (SSPG) Test

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2 Infection and Inflammation in Human Adipose Tissue
Plain-language title
Studies fat tissue in long COVID, obesity and insulin resistanceGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05833217, who can take part
Record updated
4 December 2024